Title: COTC034: Clinical, molecular, and immune characterization of naturally occurring osteosarcoma in dogs
Investigators:
Corey Saba, DVM, DACVIM (Oncology faculty)
If interested, please have your primary veterinarian request additional information through the UGA Oncology service by calling the small animal referral coordinator at 706-542-5362.
Study description:
The purposes of this study are to evaluate the disease-free interval (i.e. time to cancer progression), proportion of dogs that are disease free at 15-weeks post-operatively, and the 1-year and 2-year overall survival rates of dogs diagnosed with appendicular osteosarcoma undergoing amputation alone. Dogs will NOT receive systemic chemotherapy while on the trial. Dogs must have a cytology or biopsy confirmed diagnosis of appendicular osteosarcoma to be eligible for participation in this study. In addition the following conditions must be met:
Inclusion criteria:
- Dogs must be otherwise healthy and have adequate organ function.
- Dogs must weigh ≥ 25.0 kg.
- At the time of screening, dogs must have measurable disease amenable to limb amputation
with no evidence of distant metastasis. - Owners must sign a consent form including consent for necropsy upon the dog’s death.
** Dogs receiving any previous surgery (for osteosarcoma), previous or concurrent chemotherapy (including bisphosphonates), immunotherapy and/or radiation therapy are not eligible for this trial.
Dogs will undergo physical examination, routine laboratory testing and imaging, and tumor biopsies to determine eligibility. All dogs will undergo limb amputation at UGA, and will be expected to return for scheduled recheck visits every 3-6 weeks to look for cancer progression. These visits are required for inclusion in the study.
Owners are responsible for the costs of initial evaluation and staging. Once a dog is enrolled, the study will cover the cost the amputation and all subsequent office visits and diagnostic tests required by the study.
Duration of study: The study is OPEN.
Potential benefits to veterinary medicine: These data will be used to better characterize this common cancer in large and giant breed dogs.
